Imperial College London

DrDipenderGill

Faculty of MedicineSchool of Public Health

Clinical Research Fellow
 
 
 
//

Contact

 

+44 (0)7904 843 810dipender.gill

 
 
//

Location

 

School of a Public HealthMedical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Yuan:2023:10.1016/j.ebiom.2023.104488,
author = {Yuan, S and Wang, L and Zhang, H and Xu, F and Zhou, X and Yu, L and Sun, J and Chen, J and Ying, H and Xu, X and Yu, Y and Spiliopoulou, A and Shen, X and Wilson, J and Gill, D and Theodoratou, E and Larsson, SC and Li, X},
doi = {10.1016/j.ebiom.2023.104488},
journal = {EBIOMEDICINE},
title = {Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases},
url = {http://dx.doi.org/10.1016/j.ebiom.2023.104488},
volume = {89},
year = {2023}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Yuan,S
AU - Wang,L
AU - Zhang,H
AU - Xu,F
AU - Zhou,X
AU - Yu,L
AU - Sun,J
AU - Chen,J
AU - Ying,H
AU - Xu,X
AU - Yu,Y
AU - Spiliopoulou,A
AU - Shen,X
AU - Wilson,J
AU - Gill,D
AU - Theodoratou,E
AU - Larsson,SC
AU - Li,X
DO - 10.1016/j.ebiom.2023.104488
PY - 2023///
SN - 2352-3964
TI - Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases
T2 - EBIOMEDICINE
UR - http://dx.doi.org/10.1016/j.ebiom.2023.104488
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000953265600001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
VL - 89
ER -